Felix Biotechnology announces initiation of the CYPHY Phase 1/2 study at Yale for its lead asset targeting P. aeruginosa infections
Share this article Share this article SAN FRANCISCO, Jan. 7, 2021 /PRNewswire/ -- Felix Biotechnology today announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, placebo-controlled study ( NCT 04684641) will assess the safety and efficacy of YPT-01 added to standard antimicrobial therapy in 36 patients. CYPHY will also assess the ability of YPT-01 to reduce the virulence and antibiotic-resistance of P. aerugi...